Status:
UNKNOWN
A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)
Lead Sponsor:
Xuhua Duan
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
This is a real world study to determine the short-term efficacy and safety of Elaboration transcatheter arterial chemoembolization (E-TACE) for hepatocellular carcinoma (HCC)
Detailed Description
Primary liver cancer is the fourth common malignant tumor and the second cause of death in China, which seriously threatens the life and health of Chinese people. Hepatocellular carcinoma accounts for...
Eligibility Criteria
Inclusion
- Gender and age are not limited;
- HCC patients who strictly meet the clinical diagnostic criteria of the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2022 edition) or who have been confirmed by histopathology or cytology;
- Patients who have at least one tumor supply artery available for superselection, and who are assessed by investigators or multi-disciplinary treatment (MDT) to require E-TACE therapy;
- Patients sign informed consent and have good compliance.
Exclusion
- Patients judged by the investigators to be unsuitable for inclusion in this study.
Key Trial Info
Start Date :
September 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 10 2025
Estimated Enrollment :
298 Patients enrolled
Trial Details
Trial ID
NCT06023147
Start Date
September 10 2023
End Date
September 10 2025
Last Update
September 7 2023
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Huai He Hospital of Henan University
Kaifeng, Henan, China
2
Luo He Central Hospital
Luohe, Henan, China
3
WuYang People's Hospital
Luohe, Henan, China
4
Luo Yang Central Hospital
Luoyang, Henan, China